Oasmia's two major shareholders nominate Alexander Kotsinas to new board member
(OMX (English) Via Acquire Media NewsEdge)
In connection with Oasmia's annual general meeting on September 30, the
company's two major shareholders Alceco International S.A. and Nexttobe AB have
put forward a proposition to expand the board of Oasmia with Alexander
Kotsinas, today part of the management team of Nexttobe.
Uppsala, Sweden, 2013-09-11 09:30 CEST (GLOBE NEWSWIRE) --
“Ever since Nexttobe became a shareholder of Oasmia, there have been
discussions with the largest shareholder Alceco to strengthen the board with
one more member. Alexander’s long-time experience from the business community,
and especially the life science sector, makes him a valuable addition”,
commented Julian Aleksov, CEO of Oasmia.
Prior to joining Nexttobe, Alexander Kotsinas served as Vice President and CFO
of Q-Med AB. Previously, he held positions at Life Europe, 3 Scandinavia,
Investor and Ericsson. Alexander has a Master of Science from the Royal
Institute of Technology in Applied Physics and a Bachelor of Science from
Handelshögskolan in Stockholm.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of
human and veterinary oncology. The company’s product development aims to create
and manufacture novel nanoparticle formulations and drug-delivery systems based
on well-established cytostatics which, in comparison with current alternatives,
show improved properties, reduced side-effects, and expanded applications. The
company’s product development is based on its proprietary in-house research and
company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the
Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).
Mikael Widell, Vice President Communications, Oasmia Pharmaceutical
AB. E-mail: Mikael.email@example.com Mobile: +46 (0) 703 11 99 60.
www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de
Copyright © 2013 OMX AB (publ).
Copyright © 2013 OMX AB (publ)
[ Back To Technology News's Homepage ]